<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252732</url>
  </required_header>
  <id_info>
    <org_study_id>TMC-ORI-10-02</org_study_id>
    <nct_id>NCT01252732</nct_id>
  </id_info>
  <brief_title>Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection</brief_title>
  <acronym>SOLO II</acronym>
  <official_title>A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melinta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Melinta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 3 trial is to evaluate the efficacy, safety, and tolerability of&#xD;
      oritavancin in ABSSSIs, including those caused by MRSA and to evaluate the potential economic&#xD;
      benefit of oritavancin administered as a single 1200 mg IV dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, randomized, double-blind, parallel, comparative efficacy and&#xD;
      safety study of single-dose IV oritavancin/IV placebo versus IV vancomycin for 7 to 10 days&#xD;
      in adults with acute bacterial skin and skin structure infection (ABSSSI) suspected or proven&#xD;
      to be caused by Gram-positive pathogens. Approximately 960 patients will be randomized at 100&#xD;
      centers globally.&#xD;
&#xD;
      In addition, this study will characterize the PK and PK/PD properties of a single 1200 mg IV&#xD;
      dose of oritavancin and evaluate the potential health economic benefits offered by this&#xD;
      dosing strategy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Clinical Response</measure>
    <time_frame>48-72 hours after the initation of study therapy</time_frame>
    <description>Clinical response at the ECE visit (48-72 hours following initiation of study drug administration). Early clinical response was defined as a composite outcome based on, cessation of spreading or reduction in the size of baseline lesion, absence of fever and no rescue antibiotic medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessed Clinical Cure at Post Therapy Evaluation (Key Secondary Endpoint)</measure>
    <time_frame>7 to 14 days after end of therapy</time_frame>
    <description>Compared the clinical efficacy at the Post Therapy Evaluation of Oritavancin and Vancomycin based on the Investigator examination of the signs and symptoms of the primary ABSSSI; Investigator assessment of clinical cure is complete or nearly complete resolution of baseline signs and symptoms of the primary infection such that no further treatment with antibiotics is needed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&gt;= 20% Reduction in Lesion Area</measure>
    <time_frame>48-72 hours after the initation of study therapy</time_frame>
    <description>Clinical response at the ECE visit (48-72 hours following initiation of study drug administration) based on changes in ABSSSI lesion size measurements from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1019</enrollment>
  <condition>Wound Infection</condition>
  <condition>Abscess</condition>
  <condition>Systemic Inflammation</condition>
  <condition>Cellulitis</condition>
  <arm_group>
    <arm_group_label>Single-Dose IV Oritavancin Diphosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single-Dose IV Oritavancin Diphosphate</intervention_name>
    <description>Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.</description>
    <arm_group_label>Single-Dose IV Oritavancin Diphosphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Vancomycin</intervention_name>
    <description>Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.</description>
    <arm_group_label>IV Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects may be included in the study if they meet all of the following inclusion criteria:&#xD;
&#xD;
          1. Males or females ≥18 years old&#xD;
&#xD;
          2. Diagnosis of ABSSSI suspected or confirmed to be caused by a Gram-positive pathogen&#xD;
             requiring at least 5 days of IV therapy&#xD;
&#xD;
          3. An ABSSSI includes one of the following infections Wound infections,&#xD;
             Cellulitis/erysipelas, Major cutaneous abscess&#xD;
&#xD;
          4. ABSSSI must present with at least 2 signs and symptoms&#xD;
&#xD;
          5. Able to give informed consent and willing to comply with all required study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from the study if any of the following exclusion criteria apply&#xD;
        prior to randomization:&#xD;
&#xD;
          1. Prior systemic or topical antibacterial therapy with activity against suspected or&#xD;
             proven Gram-positive pathogens within the preceding 14 days&#xD;
&#xD;
               -  The causative Gram-positive pathogen(s) isolated from the ABSSSI site is&#xD;
                  resistant in vitro to the antibacterial(s) that was administered with documented&#xD;
                  clinical progression, or&#xD;
&#xD;
               -  Documented failure to previous ABSSSI antibiotic therapy is available.&#xD;
                  Documentation of treatment failure must be recorded&#xD;
&#xD;
               -  Patient received a single dose of a short acting antibacterial therapy three or&#xD;
                  more days before randomization&#xD;
&#xD;
          2. Infections associated with, or in close proximity to, a prosthetic device&#xD;
&#xD;
          3. Severe sepsis or refractory shock&#xD;
&#xD;
          4. Known or suspected bacteremia at time of screening&#xD;
&#xD;
          5. ABSSSI due to or associated with any of the following:&#xD;
&#xD;
               -  Infections suspected or documented to be caused by Gram-negative pathogens --&#xD;
                  Wound infections (surgical or traumatic) and abscesses with only Gram-negative&#xD;
                  pathogens&#xD;
&#xD;
               -  Diabetic foot infections&#xD;
&#xD;
               -  Concomitant infection at another site not including a secondary ABSSSI lesion&#xD;
&#xD;
               -  Infected burns&#xD;
&#xD;
               -  A primary infection secondary to a pre-existing skin disease with associated&#xD;
                  inflammatory changes&#xD;
&#xD;
               -  Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular&#xD;
                  disease&#xD;
&#xD;
               -  Any evolving necrotizing process gangrene or infection suspected or proven to be&#xD;
                  caused by Clostridium species&#xD;
&#xD;
               -  Infections known to be caused by a Gram-positive organism with a vancomycin MIC&#xD;
                  &gt;2 μg/mL or clinically failing prior therapy with glycopeptides&#xD;
&#xD;
               -  Catheter site infections&#xD;
&#xD;
          6. Allergy or intolerance to aztreonam or metronidazole in a patient with suspected or&#xD;
             proven polymicrobial wound infection involving Gram-negative and/or anaerobic bacteria&#xD;
&#xD;
          7. Currently receiving chronic systemic immunosuppressive therapy&#xD;
&#xD;
          8. AIDS with CD4 count &lt; 200 cells/mm3&#xD;
&#xD;
          9. Neutropenia&#xD;
&#xD;
         10. Significant or life-threatening condition that would confound or interfere with the&#xD;
             assessment of the ABSSSI&#xD;
&#xD;
         11. Women who are pregnant or nursing&#xD;
&#xD;
         12. History of immune-related hypersensitivity reaction to glycopeptides&#xD;
&#xD;
         13. Patients that require anticoagulant monitoring with an aPTT&#xD;
&#xD;
         14. Contraindication to vancomycin&#xD;
&#xD;
         15. Patients unwilling to forego blood and/or blood product donation&#xD;
&#xD;
         16. Treatment with investigational medicinal product within 30 days before enrollment and&#xD;
             for the duration of the study&#xD;
&#xD;
         17. Investigational device present, or removed &lt;30 days before enrollment, or presence of&#xD;
             device-related infection&#xD;
&#xD;
         18. Patients unlikely to adhere to the protocol, comply with study drug administration, or&#xD;
             complete the clinical study&#xD;
&#xD;
         19. Severe hepatic disease&#xD;
&#xD;
         20. Presence of hyperuricemia&#xD;
&#xD;
         21. Unwilling to refrain from chronic use of any medication with antipyretic properties&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G. Ralph Corey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sharp Grossmont Hospital</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <results_first_submitted>March 17, 2021</results_first_submitted>
  <results_first_submitted_qc>March 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2021</results_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABSSSI</keyword>
  <keyword>Skin Infection</keyword>
  <keyword>Abscess</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Abscess</mesh_term>
    <mesh_term>Cellulitis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Oritavancin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single-Dose 1200 mg Oritavancin</title>
          <description>Single 1200 mg IV Dose of Oritavancin Diphosphate administered as first infusion followed by IV placebo administered twice daily for a minimum of 7 days up to a maximum of 10 days.</description>
        </group>
        <group group_id="P2">
          <title>Vancomycin</title>
          <description>IV Vancomycin, 1g or 15mg/kg administered twice daily for a minimum of 7 days up to a maximum of 10 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="509">Randomized</participants>
                <participants group_id="P2" count="510">Randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent to Treat Population</title>
              <participants_list>
                <participants group_id="P1" count="503"/>
                <participants group_id="P2" count="502"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="455"/>
                <participants group_id="P2" count="446"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified Intent to Treat (mITT) population</population>
      <group_list>
        <group group_id="B1">
          <title>Single-Dose 1200 mg Oritavancin</title>
          <description>Single 1200 mg IV Dose of Oritavancin Diphosphate administered as first infusion followed by IV placebo administered twice daily for a minimum of 7 days up to a maximum of 10 days.</description>
        </group>
        <group group_id="B2">
          <title>Vancomycin</title>
          <description>IV Vancomycin, 1g or 15mg/kg administered twice daily for a minimum of 7 days up to a maximum of 10 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="503"/>
            <count group_id="B2" value="502"/>
            <count group_id="B3" value="1005"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="13.40"/>
                    <measurement group_id="B2" value="44.4" spread="14.29"/>
                    <measurement group_id="B3" value="44.7" spread="13.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="324"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="338"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Early Clinical Response</title>
        <description>Clinical response at the ECE visit (48-72 hours following initiation of study drug administration). Early clinical response was defined as a composite outcome based on, cessation of spreading or reduction in the size of baseline lesion, absence of fever and no rescue antibiotic medication.</description>
        <time_frame>48-72 hours after the initation of study therapy</time_frame>
        <population>Modified intent to treat (mITT) population consisting of all patients randomized into the trial and received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Single-Dose 1200 mg Oritavancin</title>
            <description>Single 1200 mg IV Dose of Oritavancin Diphosphate administered as first infusion followed by IV placebo administered twice daily for a minimum of 7 days up to a maximum of 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>IV Vancomycin, 1g or 15mg/kg administered twice daily for a minimum of 7 days up to a maximum of 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Early Clinical Response</title>
          <description>Clinical response at the ECE visit (48-72 hours following initiation of study drug administration). Early clinical response was defined as a composite outcome based on, cessation of spreading or reduction in the size of baseline lesion, absence of fever and no rescue antibiotic medication.</description>
          <population>Modified intent to treat (mITT) population consisting of all patients randomized into the trial and received any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403"/>
                    <measurement group_id="O2" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority hypothesis test is a one sided hypothesis test performed at the 2.5% level of significance. If the lower limit of the two-sided 95% CI for the difference in response rates in the mITT population is greater than -10% the NI of oritavancin to vancomycin is concluded.</non_inferiority_desc>
            <param_type>Difference in Proportions</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.5</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessed Clinical Cure at Post Therapy Evaluation (Key Secondary Endpoint)</title>
        <description>Compared the clinical efficacy at the Post Therapy Evaluation of Oritavancin and Vancomycin based on the Investigator examination of the signs and symptoms of the primary ABSSSI; Investigator assessment of clinical cure is complete or nearly complete resolution of baseline signs and symptoms of the primary infection such that no further treatment with antibiotics is needed</description>
        <time_frame>7 to 14 days after end of therapy</time_frame>
        <population>Modified intent to treat (mITT) population consisting of all patients randomized into the trial and received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Single-Dose 1200 mg Oritavancin</title>
            <description>Single 1200 mg IV Dose of Oritavancin Diphosphate administered as first infusion followed by IV placebo administered twice daily for a minimum of 7 days up to a maximum of 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>IV Vancomycin, 1g or 15mg/kg administered twice daily for a minimum of 7 days up to a maximum of 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Assessed Clinical Cure at Post Therapy Evaluation (Key Secondary Endpoint)</title>
          <description>Compared the clinical efficacy at the Post Therapy Evaluation of Oritavancin and Vancomycin based on the Investigator examination of the signs and symptoms of the primary ABSSSI; Investigator assessment of clinical cure is complete or nearly complete resolution of baseline signs and symptoms of the primary infection such that no further treatment with antibiotics is needed</description>
          <population>Modified intent to treat (mITT) population consisting of all patients randomized into the trial and received any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416"/>
                    <measurement group_id="O2" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority hypothesis test is a one sided hypothesis test performed at the 2.5% level of significance. If the lower limit of the two-sided 95% CI for the difference in response rates in the mITT population is greater than -10% the NI of oritavancin to vancomycin is concluded.</non_inferiority_desc>
            <param_type>Difference in Proportions</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>7.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>&gt;= 20% Reduction in Lesion Area</title>
        <description>Clinical response at the ECE visit (48-72 hours following initiation of study drug administration) based on changes in ABSSSI lesion size measurements from baseline.</description>
        <time_frame>48-72 hours after the initation of study therapy</time_frame>
        <population>Modified intent to treat (mITT) population consisting of all patients randomized into the trial and received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Single-Dose 1200 mg Oritavancin</title>
            <description>Single 1200 mg IV Dose of Oritavancin Diphosphate administered as first infusion followed by IV placebo administered twice daily for a minimum of 7 days up to a maximum of 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>IV Vancomycin, 1g or 15mg/kg administered twice daily for a minimum of 7 days up to a maximum of 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>&gt;= 20% Reduction in Lesion Area</title>
          <description>Clinical response at the ECE visit (48-72 hours following initiation of study drug administration) based on changes in ABSSSI lesion size measurements from baseline.</description>
          <population>Modified intent to treat (mITT) population consisting of all patients randomized into the trial and received any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="432"/>
                    <measurement group_id="O2" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority hypothesis test is a one sided hypothesis test performed at the 2.5% level of significance. If the lower limit of the two-sided 95% CI for the difference in response rates in the mITT population is greater than -10% the NI of oritavancin to vancomycin is concluded.</non_inferiority_desc>
            <param_type>Difference in Proportions</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Begins from the time the patient provided informed consent through to the last follow up visit at 60 (+7) days.</time_frame>
      <desc>Additional Description Adverse events were analysed in the safety population consisting of all patients who received any study drug. The analysis was performed according to the actual treatment that the patient received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Single-Dose 1200 mg Oritavancin</title>
          <description>Single 1200 mg IV Dose of Oritavancin Diphosphate administered as first infusion followed by IV placebo administered twice daily for a minimum of 7 days up to a maximum of 10 days.</description>
        </group>
        <group group_id="E2">
          <title>Vancomycin</title>
          <description>IV Vancomycin, 1g or 15mg/kg administered twice daily for a minimum of 7 days up to a maximum of 10 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Electromechanical dissociation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Rectal Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Non-cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactoid Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Necrotizing Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Wound Infection Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Abscess Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Extradural Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Intervertebral Discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Skin Bacterial Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Leukocytoplastic Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="272" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="265" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>infusion site phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Fusaro</name_or_title>
      <organization>Melinta Therapeutics, Inc.</organization>
      <phone>6098270956</phone>
      <email>kfusaro@melinta.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

